ortho·cell
advancing tissue repair & regeneration

Notice under Section 708A(5)(e) of the Corporations Act

Orthocell Limited ("Issuer") notifies ASX (as the operator of the prescribed financial market on which the securities identified below are or are to be quoted) under section 708A(5)(e) of the Corporations Act that:

1. the securities identified below were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

2. as at the date of this notice the Issuer has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Issuer and with section 674 of the Corporations Act; and

3. as at the date of this notice there is no information:

   (a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and

   (b) that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:

      (i) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or

      (ii) the rights and liabilities attaching to the securities,

   to the extent that it would be reasonable for investors and their professional advisers to expect to find such information in a disclosure document.

DETAILS OF THE SECURITIES ISSUED	
Class of Securities:	Ordinary Shares
ASX Code of the Securities:	OCC
Date of the issue of securities:	18 November 2021
Total number of Shares issued:	288,194

Release authorised by The Board of Directors of the Company.

For more information, please contact:

General & Investor enquiries
Paul Anderson
Orthocell Limited
Managing Director
P: +61 8 9360 2888

E: paul.anderson@orthocell.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of dental, nerve and orthopaedic, reconstructive applications. Orthocell recently received FDA 510(k) approval for Striate+, the first application of the CelGro® platform for dental GBR applications. Striate+ is also approved in Australia (ARTG) and Europe (CE Mark) for the same. The Company's other major products are the cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue respectively. Orthocell is moving forward with Ortho-ATI® clinical studies designed to assist in the US (FDA) approval process and has completed its pre-IND meetings with the FDA.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter **@Orthocellltd** and LinkedIn www.linkedin.com/company/orthocell-ltd